Key result
Dexrazoxane specifically abolished doxorubicin-induced DNA damage in cardiomyocytes by antagonizing Top2 cleavage complex formation and inducing rapid degradation of Top2beta.
Why the study?
Does dexrazoxane prevent doxorubicin-induced DNA damage in cardiomyocytes via Top2beta interference?
Does dexrazoxane prevent doxorubicin-induced DNA damage in cardiomyocytes via Top2beta interference?
Dexrazoxane protects against doxorubicin cardiotoxicity by antagonizing doxorubicin-induced DNA damage through interference with Top2beta.
Answers are grounded in this paper and cite their sources.
Does not support changes in dexrazoxane use; leaves open clinical translation of Top2β-mediated cardioprotection.
Doxorubicin is among the most effective and widely used anticancer drugs in the clinic. However, cardiotoxicity is one of the life-threatening side effects of doxorubicin-based therapy. Dexrazoxane (Zinecard, also known as ICRF-187) has been used in the clinic as a cardioprotectant against doxorubicin cardiotoxicity. The molecular basis for doxorubicin cardiotoxicity and the cardioprotective effect of dexrazoxane, however, is not fully understood. In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes. Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta). Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage. Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity. The specific involvement of proteasome and Top2beta in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.
No takes yet. Share an insight, caveat, or question.
Lyu et al. (2007) studied Doxorubicin cardiotoxicity. Dexrazoxane vs. Doxorubicin alone was evaluated on DNA damage signal gamma-H2AX. Dexrazoxane specifically abolished doxorubicin-induced DNA damage in cardiomyocytes by antagonizing Top2 cleavage complex formation and inducing rapid degradation of Top2beta.
Synapse has enriched 10 related papers. Consider them for comparative context: